A Research Guide for
Facing Melanoma

PRACTICE-CHANGING The NADINA trial demonstrated that giving nivolumab + ipilimumab before surgery (neoadjuvant) for resectable Stage III melanoma dramatically improved event-free survival compared to adjuvant nivolumab alone after surgery. Two cycles of neoadjuvant immunotherapy achieved major pathological response (MPR) in approximately 60% of patients. This is rapidly becoming the new standard of care for macroscopic Stage III melanoma.

FDA-APPROVED KEYNOTE-716 showed that pembrolizumab given after surgery for Stage IIB and IIC melanoma (thick primary tumors without known lymph node involvement) significantly reduced the risk of recurrence. This was important because Stage IIB/IIC melanoma has a recurrence risk similar to Stage IIIA/IIIB, yet had no approved adjuvant therapy until this trial.

FDA-APPROVED Lifileucel (Amtagvi) is the first tumor-infiltrating lymphocyte (TIL) therapy approved by the FDA (February 2024) for unresectable or metastatic melanoma previously treated with a PD-1 inhibitor and, if BRAF V600 mutant, a BRAF inhibitor. TIL therapy involves extracting immune cells from the patient’s own tumor, expanding them billions-fold in the laboratory, and reinfusing them. The C-144-01 trial showed an overall response rate of approximately 31% with durable responses in heavily pretreated patients.

FDA-APPROVED Opdualag combines nivolumab (anti-PD-1) with relatlimab (anti-LAG-3), targeting a second immune checkpoint. The RELATIVITY-047 trial showed Opdualag improved progression-free survival over nivolumab alone in previously untreated advanced melanoma, with a more favorable toxicity profile than nivolumab + ipilimumab.

INVESTIGATIONAL mRNA-4157 (V940), developed by Moderna and Merck, is a personalized cancer vaccine using mRNA technology to teach the immune system to recognize specific mutations (neoantigens) unique to each patient’s tumor. The KEYNOTE-942 Phase IIb trial showed that V940 + pembrolizumab reduced the risk of recurrence or death by 44% compared to pembrolizumab alone in resected high-risk Stage III/IV melanoma. The Phase III trial (V940-001 / INTerpath-001, NCT05933577) is ongoing.

FDA-APPROVED Tebentafusp is a bispecific T-cell engager approved for HLA-A*02:01–positive adults with unresectable or metastatic uveal melanoma. The IMCgp100-202 trial showed it improved overall survival compared to investigator’s choice therapy. This is the first and only approved systemic therapy shown to improve survival in metastatic uveal melanoma, a disease that historically did not respond to standard immunotherapy.

• Excisional biopsy (preferred): The entire suspicious lesion is removed with a narrow margin (1–3 mm) of normal skin. This is the gold standard because it allows the pathologist to assess the full thickness and breadth of the lesion.
• Incisional or punch biopsy: A portion of the lesion is removed. Acceptable when a lesion is too large for complete excision or is in a cosmetically sensitive area (face, ears). May not capture the deepest point.
• Shave biopsy: Generally not recommended for suspected melanoma because it may transect the base of the tumor, making accurate measurement of Breslow thickness impossible.

Key point: If you have a suspicious mole, ask your dermatologist about excisional biopsy. Accurate depth measurement (Breslow thickness) from the initial biopsy drives all subsequent decisions.

The pathology report from your biopsy contains several critical measurements:

• Breslow thickness: The most important prognostic factor. Measured in millimeters from the top of the epidermis to the deepest melanoma cell. Thinner is better: ≤1.0 mm is considered thin melanoma with excellent prognosis.
• Ulceration: Whether the surface of the melanoma has broken down. Ulceration worsens prognosis and affects staging.
• Mitotic rate: How rapidly the melanoma cells are dividing. Higher rates indicate more aggressive disease.
• Clark level: How deeply the melanoma has invaded into the layers of skin. Less commonly used now than Breslow thickness.
• Margins: Whether cancer cells extend to the edges of the biopsy specimen.
• Lymphovascular invasion: Whether melanoma cells have invaded blood or lymph vessels. If present, may indicate higher risk of spread.
• Microsatellites: Nests of tumor cells separated from the primary tumor by normal tissue. Upstage the disease.

Stage can feel like an intimidating verdict, but it is really a shorthand for two practical questions: how far has the melanoma gone, and what does that mean for treatment. In broad strokes, Stage I and II melanoma is confined to the skin where it started, and the difference between them is mostly thickness (and whether the surface is ulcerated) — these are usually treated by surgery, with Stage II's thicker tumors sometimes adding medicine afterward to lower the chance of return. Stage III means melanoma cells have reached nearby lymph nodes or the skin/tissue between the tumor and those nodes; treatment combines surgery with immunotherapy (increasingly given before surgery). Stage IV means spread to distant organs, and is treated primarily with immunotherapy and, for BRAF-mutant disease, targeted therapy. A few things make the numbers less frightening. The survival figures attached to each stage are averages from past data and, for the advanced stages especially, badly understate today's results because they predate or only partly include the immunotherapy era. Within a stage there is a wide range — a "Stage III" can be quite favorable or higher-risk depending on the details — so your specific substage and features matter more than the broad label. And staging is not destiny: it sets the strategy, but how your individual melanoma responds to treatment is what ultimately shapes your course. Ask your team to walk you through your exact substage and what it means for your plan, rather than reading a survival percentage off a chart.

• What is my Breslow thickness and is there ulceration?
• What is my exact AJCC stage?
• Do I need a sentinel lymph node biopsy?
• Should I have imaging scans (CT, PET/CT, MRI brain)?
• Has my tumor been tested for BRAF and other mutations?
• Do I need to see a surgical oncologist, medical oncologist, or both?
• Should I get a second pathology opinion at a melanoma center?
• Given my stage, what are my treatment options?

BRAF is the most commonly mutated gene in melanoma. The V600E mutation accounts for approximately 90% of BRAF mutations, with V600K comprising most of the remainder.

Why it matters: BRAF-mutant melanoma can be treated with BRAF/MEK inhibitor combinations (dabrafenib + trametinib, encorafenib + binimetinib), which produce rapid tumor shrinkage in most patients. BRAF status also influences the choice between immunotherapy and targeted therapy in first-line treatment.

When to test: BRAF testing is mandatory for all Stage III and IV melanoma at diagnosis. Testing is also recommended for Stage IIC melanoma and may inform adjuvant therapy decisions.

NRAS-mutant melanoma is associated with older age, thicker tumors, and chronic sun damage. There are no FDA-approved NRAS-specific targeted therapies, but NRAS mutation status has prognostic value and may guide clinical trial enrollment. MEK inhibitor trials have shown modest activity.

KIT mutations are rare in common cutaneous melanoma but are found at higher rates in mucosal melanoma, acral melanoma, and melanoma arising from chronically sun-damaged skin. Imatinib (Gleevec) has shown activity in KIT-mutant melanoma, particularly with specific mutations in exons 11 and 13.

• PD-L1 expression: May predict response to anti-PD-1 therapy, although patients with PD-L1 negative tumors can still respond. Not used to exclude immunotherapy.
• Tumor mutational burden (TMB): Higher TMB is associated with better response to immunotherapy. Melanoma generally has high TMB due to UV-induced mutations.
• GNAQ/GNA11: Found in ~80% of uveal melanoma. Not targetable with current approved therapies but identifies uveal melanoma biology.
• NF1 mutations: Found in ~10–15% of cutaneous melanoma, often in older patients with extensive sun damage.
• Gene expression profiling (GEP): Tests like DecisionDx-Melanoma and Merlin Assay can help predict recurrence risk in early-stage melanoma. Not yet incorporated into NCCN staging but may guide surveillance intensity.

You may hear that your tumor is being sent for "molecular" or "genetic" testing, and it is worth understanding what this is and is not. These tests look at the genes within the melanoma tumor itself — they are not testing the genes you inherited or that you might pass to children (that is a separate kind of testing, discussed under family screening). The single most important result is BRAF: roughly 40–50% of melanomas carry a BRAF mutation, and a positive result unlocks an entire additional class of treatment (BRAF/MEK inhibitor pills) and helps your team plan the sequence of therapies. This is why BRAF testing is standard for all Stage III and IV melanoma. Other results matter mainly for specific situations: KIT mutations (more common in melanomas of the palms, soles, nail beds, and mucous membranes) can open another targeted option; GNAQ/GNA11 identifies the distinct biology of eye (uveal) melanoma; and markers like PD-L1 and tumor mutational burden give clues about immunotherapy response without ever being used to deny you treatment. A practical note: a positive BRAF result does not automatically mean you start with the BRAF pills — for most people immunotherapy is still tried first because its benefits last longer, and the targeted option is held in reserve. The key thing to confirm is simply that the appropriate testing has been done, because it ensures none of your options are overlooked.

After the diagnostic biopsy, a wider excision is performed to ensure no cancer cells remain at the margins. The recommended surgical margins depend on Breslow thickness:

Sentinel lymph node biopsy determines whether melanoma has spread to the nearest draining lymph node(s). A radioactive tracer and/or blue dye is injected near the melanoma site, and the first lymph node(s) to receive drainage (the sentinel node) are removed and examined.

When SLNB is recommended (ASCO/SSO guidelines):

• Breslow thickness >0.8 mm
• Breslow ≤0.8 mm with ulceration
• Consider for tumors 0.8–1.0 mm with other high-risk features (high mitotic rate, lymphovascular invasion, young age)

A positive sentinel node: Upstages the disease to Stage III and may make the patient eligible for adjuvant or neoadjuvant therapy. Completion lymph node dissection is no longer routinely recommended for positive sentinel nodes based on the MSLT-II and DeCOG-SLT trials, which showed no survival benefit from immediate complete dissection; instead, close surveillance with ultrasound is the standard.

For early-stage melanoma, surgery is usually far less daunting than people fear. Wide local excision is most often an outpatient procedure done under local anesthesia (you are awake, the area numbed) for smaller lesions, or with sedation or general anesthesia for larger ones or when a sentinel node biopsy is done at the same time. The surgeon removes the area of the previous biopsy plus a margin of normal-looking skin around and beneath it, then closes the wound — usually with stitches, sometimes with a skin graft or a small flap if the area is large or on a cosmetically tricky site like the face. Recovery for most people is a matter of wound care over a couple of weeks: keeping it clean and dry, watching for signs of infection, limiting strenuous activity that stretches the area, and attending a follow-up to remove stitches and review the final pathology. A scar is expected; its size depends on the tumor's thickness and location, and a plastic or reconstructive surgeon may be involved for difficult areas. If a sentinel node biopsy is performed, there may be a small additional incision near the relevant lymph-node basin and a low risk of fluid collection or, less commonly, lymphedema. The honest reassurance is that for the great majority of melanomas — the thin, early ones — this surgery is the whole treatment and is highly likely to be curative.

FDA-APPROVED

• KEYNOTE-054 (Stage III): Pembrolizumab after complete resection of Stage III melanoma reduced recurrence risk by approximately 35% compared to placebo. Given as 200 mg IV every 3 weeks for up to 1 year. (NCT02362594)
• KEYNOTE-716 (Stage IIB/IIC): Pembrolizumab in Stage IIB and IIC melanoma after surgery improved recurrence-free survival (RFS), the primary endpoint. This expanded the use of adjuvant immunotherapy to earlier-stage, high-risk disease. (NCT03553836)
• CheckMate 76K (Stage IIB/IIC): Nivolumab is also FDA-approved (October 2023) as adjuvant therapy for completely resected Stage IIB or IIC melanoma in patients 12 and older — it reduced the risk of recurrence or death by about 58% versus placebo. This gives a second approved adjuvant immunotherapy option for high-risk Stage II disease. (NCT04099251)

Common side effects: Fatigue, rash, diarrhea, thyroid dysfunction, and immune-related adverse events (see immunotherapy section).

FDA-APPROVED CheckMate 238 showed nivolumab was superior to ipilimumab as adjuvant therapy for Stage IIIB–IV resected melanoma, with significantly better recurrence-free survival and fewer side effects. (NCT02388906)

FDA-APPROVED The COMBI-AD trial showed dabrafenib + trametinib (BRAF/MEK inhibitor combination) reduced recurrence risk by approximately 50% in BRAF V600-mutant Stage III melanoma after complete resection. Treatment duration is 12 months. (NCT01682083)

This is an option specifically for BRAF V600-mutant melanoma. The choice between adjuvant immunotherapy and adjuvant targeted therapy for BRAF-mutant Stage III melanoma should be discussed with your oncologist based on individual factors.

Adjuvant therapy after surgery is one of the more genuinely personal decisions in melanoma, and understanding the trade-off helps you make it with your oncologist rather than feeling it is simply prescribed. The benefit is real: these treatments meaningfully lower the chance that melanoma comes back. But two honest caveats shape the decision. First, the trials have mostly shown that adjuvant therapy delays or prevents recurrence; for many people it is not yet proven to extend overall life compared with watching closely and treating a recurrence if one happens — and effective treatment is available at that later point too. Second, a substantial number of people who take adjuvant therapy would never have had a recurrence anyway, which means some are exposed to side effects for no personal benefit — and immunotherapy's side effects, while usually manageable, occasionally include permanent ones such as a thyroid or other hormone gland that needs lifelong replacement. This balance tips differently depending on your risk: the higher your individual chance of recurrence, the more the benefit outweighs the downside, while for lower-risk situations close surveillance is a perfectly legitimate choice that guidelines endorse. There is rarely a single "right" answer. Good questions to ask are: "What is my actual recurrence risk with and without this treatment?", "Are the side effects mostly reversible?", and "Is careful monitoring a reasonable alternative for someone like me?" This is a decision to make together, weighing your numbers, the permanence of possible side effects, and your own preferences.

PRACTICE-CHANGING The NADINA trial (2024) randomized patients with resectable Stage III melanoma to either:

• Neoadjuvant arm: 2 cycles of ipilimumab + nivolumab before surgery, followed by response-adapted adjuvant therapy
• Standard arm: Surgery first, then 12 months of adjuvant nivolumab

Results showed the neoadjuvant arm had significantly better event-free survival, with approximately 60% achieving a major pathological response (MPR). Patients with MPR had excellent outcomes and could potentially avoid prolonged adjuvant therapy. (NCT04949113)

PRACTICE-CHANGING SWOG S1801 compared neoadjuvant pembrolizumab (3 doses before surgery) + adjuvant pembrolizumab (15 doses after surgery) versus adjuvant pembrolizumab alone (18 doses after surgery) in resectable Stage IIIB–IV melanoma. The neoadjuvant + adjuvant approach significantly improved event-free survival (72% vs. 49% at 2 years). (NCT03698019)

It can seem backwards to treat melanoma with medicine before removing it surgically, so it helps to understand why this order — called neoadjuvant therapy — has become preferred for melanoma that has reached the lymph nodes (macroscopic Stage III). The science is that immunotherapy works better when the tumor is still present: the cancer acts as a "training target" that helps your immune system learn to recognize melanoma cells, including any microscopic ones hiding elsewhere, far more effectively than it can after the obvious tumor is gone. In practice this usually means a short course of immunotherapy (often two cycles) over several weeks, then surgery. There is a second, almost as important benefit: when the surgeon removes the tumor, the pathologist examines exactly how much living cancer remains, which is a powerful, personalized read on how well the immunotherapy worked for you. If little or no living tumor is left — which happens in roughly 60% of patients — your outlook is excellent and you may be able to skip or shorten further treatment; if more remains, your team knows to add treatment afterward. So the approach not only improves outcomes but tailors the rest of your plan to your own response. The main considerations to discuss are the side effects of the immunotherapy (especially if a combination is used) and the short delay before surgery, which is generally safe for the kind of melanoma this approach is used for.

FDA-APPROVED PD-1 (programmed death-1) is a protein on T cells that acts as an “off switch,” preventing them from attacking. Melanoma cells exploit this by expressing PD-L1, which binds PD-1 and shuts down the immune response. Anti-PD-1 antibodies block this interaction, reactivating the immune attack.

• Pembrolizumab (Keytruda): Given as IV infusion every 3 or 6 weeks. Response rate approximately 33–40% in advanced melanoma as monotherapy.
• Nivolumab (Opdivo): Given as IV infusion every 2 or 4 weeks. Similar efficacy to pembrolizumab.

Response can be durable. In long-term follow-up studies, many patients who respond to anti-PD-1 therapy remain in remission for years, even after stopping treatment.

FDA-APPROVED Combining ipilimumab (anti-CTLA-4) with nivolumab (anti-PD-1) provides the highest response rates in melanoma but also the highest toxicity. Key data from CheckMate 067:

• Overall response rate: ~58%
• 6.5-year overall survival: ~49% (unprecedented for metastatic melanoma)
• Complete response rate: ~22%
• Grade 3–4 adverse events: ~59% (significantly higher than single agent)

Despite higher toxicity, this combination is often preferred for patients with brain metastases, large tumor burden, or PD-L1 negative tumors.

Immunotherapy side effects are fundamentally different from chemotherapy. By activating the immune system, these drugs can cause inflammation in virtually any organ. Common immune-related adverse events (irAEs) include:

• Skin: Rash, itching (most common, usually manageable)
• Gastrointestinal: Diarrhea, colitis (can be severe; report immediately if >4 stools/day above baseline)
• Endocrine: Thyroid dysfunction (hypothyroidism or hyperthyroidism), adrenal insufficiency, hypophysitis (pituitary inflammation), type 1 diabetes (rare)
• Liver: Hepatitis (elevated liver enzymes, usually detected on blood tests before symptoms)
• Lung: Pneumonitis (cough, shortness of breath — report immediately)
• Kidney, heart, neurologic: Less common but potentially serious

Critical rule: Report any new symptoms to your oncology team promptly. Most immune side effects are manageable if caught early. Treatment involves holding immunotherapy and often giving corticosteroids. Delays in recognizing irAEs can lead to serious organ damage.

Immunotherapy is given as an intravenous infusion in an oncology clinic, and the day-to-day experience surprises many people because it is usually far gentler than the chemotherapy they imagine. A single-agent anti-PD-1 infusion (pembrolizumab or nivolumab) takes about 30–60 minutes and is given every few weeks; many people feel essentially normal and continue working and ordinary activities throughout. There is no hair loss and typically little nausea from the drugs themselves. The most common everyday effect is fatigue, along with the possibility of the immune side effects described above. Combination immunotherapy (ipilimumab plus nivolumab) is more intensive — given in a set of induction doses before moving to maintenance — and carries a meaningfully higher chance of side effects, so it involves closer monitoring. Before and during treatment you will have regular blood tests (checking thyroid, liver, and other markers) that often catch a developing side effect before you feel anything. One genuinely different feature of immunotherapy is how it works over time: responses can take weeks to months to appear, scans early on can even look briefly worse before improving, and — remarkably — when immunotherapy works it can keep working long after treatment stops, with some people remaining in remission for years off all therapy. Patience and steady monitoring, rather than dramatic day-of-infusion effects, define the experience.

The single most important thing you can do during immunotherapy is to report new symptoms early, because immune side effects are very manageable when caught promptly and can become serious if ignored. These drugs work by taking the brakes off your immune system, which occasionally lets it inflame a healthy organ — the gut (diarrhea/colitis), thyroid or other glands, liver, lungs, skin, and rarely the heart. The key mindset shift is that a symptom you might normally wait out — new or worsening diarrhea, a persistent cough or breathlessness, unusual fatigue or dizziness, yellowing skin, a fast or irregular heartbeat, severe rash — deserves a same-day call to your oncology team rather than a wait-and-see approach. Practical steps make this reliable: keep your team's after-hours number handy, carry a wallet card or note stating that you are on immunotherapy (so any emergency clinician knows your symptoms may be immune-related and that ordinary treatment may differ), and do not start steroids or other medicines for a new symptom without checking, since some interact with the management plan. Most side effects are handled by briefly pausing the drug and, if needed, a course of steroids, after which many people resume treatment. You are not being a nuisance by calling — early reporting is exactly what keeps immunotherapy both effective and safe.

• Which immunotherapy regimen do you recommend and why?
• What are the expected side effects, and how will we monitor for them?
• How long will I need to be on treatment?
• Am I a candidate for neoadjuvant therapy before surgery?
• Is BRAF/MEK targeted therapy an option for me?
• Should we do single-agent anti-PD-1 or combination immunotherapy?
• What signs of immune-related side effects should I report immediately?
• How will you monitor whether treatment is working?
• Are there clinical trials that might offer a better option for my situation?
• What is the plan if the first treatment does not work?

Key advantages of BRAF/MEK therapy: Very rapid responses (often within weeks), high response rates, oral medications taken at home.

Key limitation: Most patients eventually develop resistance, with median progression-free survival of approximately 11–15 months. Immunotherapy tends to produce more durable responses when it works.

• Fever (pyrexia): Common with dabrafenib + trametinib (~50% of patients). Can be high-grade. Usually manageable with dose interruption and antipyretics.
• Skin effects: Rash, photosensitivity, keratoacanthomas/cutaneous squamous cell carcinomas (paradoxical activation of MAPK pathway in normal skin). Regular dermatologic monitoring recommended.
• Cardiac: Decreased ejection fraction with MEK inhibitors (baseline and periodic echocardiograms required).
• Eye: Retinal pigment epithelial detachment with MEK inhibitors. Report any visual changes immediately.
• Fatigue, nausea, diarrhea: Common but usually manageable.

If your melanoma has a BRAF mutation and you and your oncologist choose targeted therapy, the treatment is taken as pills at home rather than infusions, which many people appreciate for the freedom it offers. The trade-off is a distinctive set of side effects and the need for steady monitoring. The most talked-about effect with dabrafenib plus trametinib is recurrent fever (pyrexia), which affects about half of users and can come with chills; it is managed by briefly pausing the drugs and using fever-reducers, and if it keeps recurring your team may switch you to a different BRAF/MEK combination that causes less of it. Other effects to know about include sun sensitivity and skin changes (your dermatologist will check your skin regularly, since these drugs can cause benign-but-removable skin growths), occasional effects on the heart's pumping (monitored with periodic echocardiograms) and the eyes (report any visual changes promptly), plus fatigue, joint aches, and digestive upset. The appeal of targeted therapy is speed — tumors often shrink within weeks, which is exactly why it is favored when disease is causing urgent problems. Its main limitation is durability: for most people the melanoma eventually learns to grow around the blockade after roughly a year, which is the central reason immunotherapy (with its more lasting responses) is usually tried first when there is time. Knowing both the quick benefit and the eventual-resistance pattern helps set realistic expectations.

For most patients with metastatic melanoma, the main first-line options are:

• Nivolumab + ipilimumab (combination immunotherapy): Highest response rates (~58%) and best long-term survival data (~49% at 6.5 years). Highest toxicity. Often preferred for patients with brain metastases or large tumor burden.
• Pembrolizumab or nivolumab (single-agent anti-PD-1): Lower toxicity. Response rates ~33–40%. Preferred for patients with favorable prognostic features or concerns about combination toxicity.
• Relatlimab + nivolumab (Opdualag): Better PFS than nivolumab alone with intermediate toxicity profile. Option for patients who want more than single-agent but are concerned about ipi/nivo combination toxicity.
• Dabrafenib + trametinib or encorafenib + binimetinib (BRAF V600 mutant only): Rapid responses. Consider if urgent tumor shrinkage is needed.

Melanoma has a high propensity to spread to the brain, affecting approximately 40–50% of patients with Stage IV disease. Historically, brain metastases carried a very poor prognosis, but modern approaches have improved outcomes:

• Ipilimumab + nivolumab: Shows intracranial response rates of approximately 46–56% in asymptomatic patients (CheckMate 204). This is now the preferred systemic treatment for melanoma brain metastases.
• Stereotactic radiosurgery (SRS): Focused radiation for a limited number of brain metastases (≤4–5, depending on size). Can be combined with immunotherapy.
• BRAF/MEK inhibitors: Also cross the blood-brain barrier, particularly dabrafenib + trametinib (COMBI-MB study).
• Whole brain radiation therapy (WBRT): Generally reserved for multiple, symptomatic lesions when SRS is not feasible. Used less frequently with the availability of effective systemic therapies.

If first-line treatment fails, options include:

• Lifileucel (Amtagvi) — TIL therapy: For patients previously treated with anti-PD-1 (and BRAF inhibitor if BRAF-mutant). ORR ~31% with durable responses.
• Switch from immunotherapy to targeted therapy (or vice versa) if BRAF-mutant.
• Ipilimumab (if not previously used): Can be given as single agent or in combination.
• T-VEC (talimogene laherparepvec): Oncolytic virus therapy injected directly into accessible tumors. Can produce local and systemic (abscopal) responses. Most effective for injectable, non-visceral disease.
• Clinical trials: Multiple novel approaches in development (see Clinical Trials section).

Few moments are harder than being told melanoma has spread to distant organs, and it is worth saying plainly that the meaning of those words has changed profoundly. Before 2011, metastatic melanoma had a median survival measured in months and almost no long-term survivors. Today, with combination immunotherapy, roughly half of patients are alive years later, a meaningful share achieve complete responses, and some appear to be functionally cured — remaining free of disease long after stopping treatment. This does not make Stage IV melanoma anything other than serious, and outcomes still vary with where the disease has spread, how much there is, the pace of growth, and molecular features. But the realistic frame is no longer "how long do I have" so much as "which of several genuinely effective treatments do we use, and in what order." Several practical points help you navigate this stage: make sure BRAF testing has been done (it opens an additional class of therapy), ask whether you have brain involvement (which is treatable but shapes the plan), ask about clinical trials and newer options like TIL therapy if standard treatment stops working, and seek care at or in consultation with a melanoma specialty center, because the sequencing of these therapies is nuanced and expertise measurably affects outcomes. Many people live well, and for a long time, with Stage IV melanoma — a sentence that simply was not true a decade and a half ago.

• Is my melanoma BRAF-mutant, and does that change my treatment approach?
• Should I start with immunotherapy or targeted therapy?
• Do I have brain metastases, and if so, what is the best approach?
• Am I a candidate for TIL therapy (lifileucel)?
• What clinical trials are available for my situation?
• What is the expected response rate and survival with the recommended treatment?
• How will you monitor treatment response?
• If the first treatment doesn’t work, what is plan B?

Uveal melanoma arises in the eye (iris, ciliary body, or choroid). It has distinct biology from cutaneous melanoma, with different driver mutations (GNAQ/GNA11 instead of BRAF/NRAS) and a pattern of metastasis almost exclusively to the liver.

• Primary treatment: Plaque brachytherapy (radiation), enucleation (eye removal) for large tumors, or proton beam therapy.
• Metastatic uveal melanoma: Historically very poor prognosis. Standard immunotherapy (anti-PD-1, ipi+nivo) has limited activity in uveal melanoma.
• Tebentafusp (Kimmtrak): The first treatment to improve overall survival in metastatic uveal melanoma. Only for HLA-A*02:01 positive patients (~45% of those of European ancestry; lower in other populations). Requires HLA typing before starting.

Mucosal melanoma arises in mucous membranes (mouth, nasal passages, gastrointestinal tract, genitourinary tract). It is not related to UV exposure, is rare (about 1% of melanoma), and is often diagnosed at advanced stages.

• Surgery is the primary treatment when feasible
• Immunotherapy is used for advanced disease but response rates are lower than cutaneous melanoma
• KIT mutations are found in up to 20–30% of mucosal melanoma — test and consider imatinib if positive

Acral melanoma occurs on the palms, soles, and under the nails (subungual). It is the most common melanoma type in people with darker skin tones. Not related to UV exposure. Key differences:

• Less likely to harbor BRAF V600 mutations (~15–20%)
• More likely to have KIT mutations (~15–20%)
• Lower tumor mutational burden — may have lower response to immunotherapy than UV-associated melanoma
• Often diagnosed at later stages due to delayed recognition

• NCCN (US): Comprehensive melanoma guidelines, updated frequently
• ESMO (Europe): Clinical practice guidelines for cutaneous melanoma
• NICE (UK): Technology appraisals determining NHS access
• Melanoma Institute Australia (MIA): World-leading melanoma research center with protocols adopted internationally
• Cancer Australia: National guidelines reflecting Australia’s extensive melanoma experience
• Health Canada / CADTH: Canadian drug access pathway
• PMDA (Japan): Japanese regulatory approvals

Following the NADINA and SWOG S1801 results, neoadjuvant immunotherapy for Stage III melanoma is being rapidly adopted internationally. Australia and the Netherlands were early leaders in neoadjuvant melanoma research (the OpACIN and PRADO trials from Netherlands Cancer Institute contributed pivotal data). The Melanoma Institute Australia has incorporated neoadjuvant protocols into routine clinical care. NCCN and ESMO guidelines are being updated to reflect this practice change. Access to neoadjuvant protocols varies by country and institution.

LARGELY SUPERSEDED High-dose IL-2 was one of the first immunotherapy approaches in melanoma, achieving durable complete responses in approximately 6–8% of patients. However, it requires ICU-level monitoring due to severe toxicity (capillary leak syndrome, hypotension, organ dysfunction). With the availability of checkpoint inhibitors offering similar or better response rates with far less toxicity, high-dose IL-2 is now rarely used as first-line therapy. Some centers still offer it in select situations.

SUPERSEDED Dacarbazine was the standard systemic treatment for metastatic melanoma for decades before 2011. Overall response rates were approximately 15–20%, with very few durable responses and no proven overall survival benefit. It has been almost entirely replaced by immunotherapy and targeted therapy. Temozolomide (oral form) was similarly limited.

DE-ADOPTED Early BRAF inhibitors (vemurafenib, dabrafenib) were initially used as single agents, producing high initial response rates but short durations of response (~6–7 months median PFS) due to rapid development of resistance through MAPK pathway reactivation. Adding a MEK inhibitor (trametinib, cobimetinib, binimetinib) significantly improved PFS and reduced paradoxical MAPK activation side effects (e.g., cutaneous squamous cell carcinomas). BRAF inhibitor monotherapy is no longer recommended.

SUPERSEDED High-dose interferon alpha-2b was the first FDA-approved adjuvant therapy for melanoma (1995). While it showed a modest improvement in relapse-free survival in some studies, it required a year of treatment with significant toxicity (flu-like symptoms, fatigue, depression, hepatotoxicity) and inconsistent overall survival benefit. It has been entirely replaced by adjuvant checkpoint inhibitors and targeted therapy, which offer better efficacy with more manageable side effect profiles.

CAUTION Various attempts to improve checkpoint inhibitor efficacy by adding other agents (GM-CSF, other cytokines, some chemotherapy combinations) have generally not shown clear benefit over standard immunotherapy regimens. The DREAMseq trial itself demonstrated that starting with immunotherapy (nivolumab + ipilimumab) before BRAF-targeted therapy was superior to the reverse sequence in BRAF-mutant melanoma.

Once you have had one melanoma, two lifelong habits do more than almost anything else to protect you: sun protection and regular skin self-examination. The reason is concrete — a personal history of melanoma raises your risk of developing a second, new melanoma well above average, and UV exposure is the main modifiable driver. Sun protection is not about never going outside; it is about reducing cumulative and intense UV: daily broad-spectrum SPF 30+ sunscreen reapplied every couple of hours outdoors, protective clothing and a wide-brimmed hat, sunglasses, seeking shade in the midday hours, and never using tanning beds. This matters especially at altitude — in places like Utah, UV intensity is markedly higher than at sea level. Equally important is becoming the expert monitor of your own skin: examine it head to toe about once a month in good light, using a mirror or a partner's help for hard-to-see areas (back, scalp, behind ears, between toes, soles, and nails), and learn what your moles normally look like so you notice change. Use the ABCDE rule and the "ugly duckling" idea — any spot that is new, changing, or simply looks different from your others deserves a dermatologist's eye. Photographs can help you track specific moles over time. These habits put the earliest possible detection of any new melanoma in your own hands, where it does the most good.

One of the least-discussed but most common challenges after melanoma treatment is the anxiety that lingers between appointments and spikes around surveillance scans — so common it has a nickname, "scanxiety." Feeling afraid that the cancer might return, scanning your own body for signs, and dreading follow-up imaging are normal responses, not signs of weakness, and they often ease with time but can persist. Several things help. Knowing the surveillance plan and its purpose can convert helpless worry into a sense of being actively watched over — recurrences caught early are more treatable, which is exactly what the schedule is for. Some people find it helps to schedule scans and results close together to shorten the waiting, to plan a distracting or comforting activity around scan days, and to bring someone to results appointments. Practical anchoring — focusing on what you can control, like sun protection and skin checks — can reduce the feeling of powerlessness. And it is important to know that this distress is treatable: oncology social workers, counselors experienced with cancer survivors, support groups (in person or online), and, when anxiety is heavy, mental-health professionals and sometimes medication all genuinely help. Tell your team if fear of recurrence is affecting your sleep, mood, or daily life — survivorship care includes your emotional health, and you do not have to white-knuckle it alone.

A natural question after a melanoma diagnosis is whether your relatives are at risk and what they should do. Most melanoma is not caused by a single inherited gene; it arises from a combination of UV exposure and the ordinary genetic luck of skin type, mole pattern, and many small risk factors. But melanoma does cluster in some families, and having a first-degree relative (parent, sibling, child) with melanoma roughly doubles a person's risk, partly through shared genes and partly through shared sun habits and skin type. The practical guidance is reassuring and simple for most families: first-degree relatives benefit from sun-protective habits and from periodic skin examinations — learning self-examination and, depending on risk, seeing a dermatologist for full-skin checks. A smaller number of families carry a genuine hereditary predisposition, suggested by patterns such as multiple relatives with melanoma, melanoma at a young age, an individual with several separate melanomas, or melanoma alongside pancreatic cancer or many atypical moles. In those situations, a referral to genetic counseling can clarify whether testing for high-risk genes (such as CDKN2A) is worthwhile and what heightened screening relatives should follow. If your family history has any of those features, mention it to your team; otherwise, encouraging your close relatives to protect their skin and get to know it is the high-value, low-anxiety step.

It is natural to want to do something through your own choices, and the honest guidance is both simpler and less restrictive than the internet suggests. There is no special "melanoma diet," no food that cures or causes melanoma, and no supplement proven to fight it; a generally healthy, balanced diet that helps you maintain strength and a healthy weight is the sensible goal, and most people on immunotherapy or targeted therapy can eat normally. Two cautions about supplements are worth knowing: high-dose antioxidant supplements are not recommended (some laboratory and observational data raise concern that they could theoretically aid tumor cells rather than the patient), and any supplement or herbal product should be reviewed with your oncology team because some interact with treatment or affect the immune system — this matters more with immunotherapy than people realize. Beyond diet, the lifestyle factors with genuine evidence are the unglamorous ones: rigorous sun protection (the single most important behavior for preventing new melanomas), not smoking, staying as physically active as you comfortably can (which helps fatigue, mood, and recovery), moderating alcohol, and protecting sleep and mental health. If you want to channel energy into something that demonstrably helps, put it into sun protection, skin self-examination, keeping your appointments, and reporting symptoms early — those are the patient actions with real impact, far more than any supplement or restrictive diet.

A cancer diagnosis brings practical and financial stress alongside the medical, and knowing where to turn early prevents a lot of avoidable difficulty. Many people with early-stage melanoma miss little or no work beyond surgery and recovery; those on immunotherapy often continue working, since infusions are periodic and many feel well, though fatigue and appointment scheduling may call for some flexibility. It is worth learning your workplace rights early — in the US, protections such as the Family and Medical Leave Act and reasonable-accommodation provisions can preserve your job and allow flexible scheduling, and a brief, factual conversation with your employer about needing time for appointments often goes more smoothly than people fear. On the financial side, modern melanoma drugs are expensive, and the key is to engage help before bills accumulate: hospital oncology social workers and financial navigators are there precisely to help with insurance authorizations and appeals, and most drug manufacturers run patient-assistance and copay-support programs that meaningfully reduce out-of-pocket cost — always ask. Nonprofit organizations (the Melanoma Research Foundation, AIM at Melanoma, CancerCare, and others) offer guidance, support communities, and sometimes financial help. Do not try to carry the logistics alone or in silence: ask your team early, "Who here helps with insurance, costs, and time off work?" Getting these supports in place protects both your treatment and your peace of mind.

Melanoma is one of the fastest-moving areas in all of cancer research, which makes clinical trials especially worth considering — not only as a last resort, but sometimes as a way to access tomorrow's standard treatment today. Trials are not just for people who have run out of options; there are studies at every stage, including ones testing whether adding a personalized vaccine to standard immunotherapy further lowers the chance of recurrence after surgery. A few points help you think it through. Joining a trial is voluntary, you can leave at any time, and you continue to receive at least the current standard of care — trials are designed so you are not denied effective treatment. Good questions to ask are what the trial is testing, what phase it is (earlier phases focus more on safety, later phases on whether something works better), whether there is a placebo and what that would mean for you, the extra time and travel involved, and what is known so far about benefits and risks. The best ways to find matching trials are to ask your oncologist directly, to ask specifically at a melanoma specialty center (which run the most studies), and to search ClinicalTrials.gov or use the matching services offered by melanoma nonprofits. Even if you ultimately choose standard treatment, asking "Is there a trial that might be a good fit for my situation?" ensures you are not missing an option that could be right for you.

Treating the melanoma you have is only part of the picture; protecting against the next one is a lifelong project that is largely in your hands. Having had one melanoma significantly raises the chance of developing another new, separate melanoma over your lifetime, so the same prevention and early-detection habits that protect the general population matter even more for you. The two pillars are reducing ultraviolet exposure and catching anything new early. For UV: make daily sun protection routine rather than occasional — broad-spectrum sunscreen, sun-protective clothing and hats, shade during peak hours, and an absolute avoidance of tanning beds, which are a proven cause of melanoma. This matters year-round and especially at altitude and on reflective surfaces like snow and water. For early detection: keep your scheduled dermatology skin examinations for life (their frequency is set by your risk), and become skilled at examining your own skin monthly, knowing that any new, changing, or "odd-one-out" spot deserves prompt evaluation. It is also worth a calm conversation with close blood relatives about their own sun protection and skin awareness, since melanoma risk has a familial component. Framing these habits not as fear but as a small, durable set of routines that genuinely lower your future risk turns an anxious "what if it comes back" into concrete, empowering action.

After your initial treatment, you move into a follow-up (surveillance) phase whose intensity is matched to your stage, and understanding the rhythm helps it feel purposeful rather than ominous. For thin, early-stage melanoma, follow-up is mostly periodic skin examinations and a clinical check, often every six to twelve months, with imaging only if a symptom raises concern. For higher-stage disease, visits are more frequent in the first two to three years — when recurrence is most likely — and typically include physical examination, skin and lymph-node checks, and scans (CT or PET/CT, and brain MRI where relevant) on a schedule, gradually spacing out over about five years before easing to mainly annual skin checks. Two features of melanoma shape this plan: most recurrences happen in the first few years (so surveillance is front-loaded), but melanoma can occasionally return many years later and survivors are at higher risk of a brand-new melanoma (so skin checks continue for life). If you had a positive sentinel node but did not have the full lymph nodes removed, you will likely have regular ultrasound of that lymph-node area. The purpose of all of this is simple and reassuring: to catch anything — a recurrence or a new melanoma — as early as possible, when it is most treatable. It is reasonable to ask your team for your specific schedule in writing, what each scan is looking for, and which symptoms should prompt a call between visits, so you know exactly what to expect and what is yours to watch for.

• Learn the treatment plan. Attend appointments when possible. Write down questions beforehand and take notes during visits.
• Watch for immune-related side effects. If your loved one is on immunotherapy, know the warning signs: new rash, persistent diarrhea, unusual fatigue, shortness of breath, headaches, vision changes. These need prompt medical attention.
• Help with skin surveillance. After melanoma treatment, regular skin checks are essential. Help monitor hard-to-see areas (back, scalp) between dermatology appointments.
• Address sun protection together. Make sun protection a household habit: sunscreen, protective clothing, shade-seeking behavior, especially in Utah’s high-altitude sun.

• Melanoma anxiety is real. Fear of recurrence is one of the most common psychological challenges after melanoma. Every skin check can trigger anxiety. Professional counseling can help.
• Connect with others. The Melanoma Research Foundation (melanoma.org, 1-877-673-6460) and AIM at Melanoma (aimatmelanoma.org) offer peer support programs and educational resources.
• Caregiver burnout. Take care of yourself. Accept help when offered. Your well-being is essential to providing good care.
• Advance care planning. For advanced melanoma, discuss goals of care, advance directives, and preferences early — when the patient is well enough to participate fully.

• “melanoma pembrolizumab adjuvant KEYNOTE-716”
• “melanoma nivolumab ipilimumab CheckMate 067”
• “melanoma neoadjuvant immunotherapy NADINA”
• “melanoma neoadjuvant pembrolizumab SWOG S1801”
• “melanoma dabrafenib trametinib COMBI-AD adjuvant”
• “melanoma relatlimab nivolumab Opdualag RELATIVITY-047”
• “melanoma TIL therapy lifileucel Amtagvi C-144-01”
• “uveal melanoma tebentafusp Kimmtrak IMCgp100”

• “melanoma personalized neoantigen vaccine mRNA-4157 V940”
• “melanoma BRAF resistance mechanisms next-generation inhibitors”
• “melanoma bispecific antibody T-cell engager”
• “melanoma combination immunotherapy novel checkpoint”
• “acral melanoma KIT mutation imatinib”
• “mucosal melanoma treatment outcomes”